ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) and European CE Mark approvals of the Durata™ defibrillation lead, the company’s next generation high voltage lead. The announcement was made at the 13th Annual International Boston Atrial Fibrillation Symposium in Boston, Mass.
